modulators of validated cancer targets like e.g. nuclear receptors and kinases.

The company’s strategy includes running the discovery and development process with limited headcounts and focusing internal activities on project management, medicinal chemistry and in vitro pharmacology. The remaining activities of the R&D process like in vivo pharmacology, toxicology and clinical trials are subcontracted to qualified providers.

The commercial goal is to license a clinical drug candidate including intellectual property and preclinical/clinical data package to a consolidated pharmaceutical or biotechnological company.